Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares traded up 5.6% on Friday . The company traded as high as $12.67 and last traded at $12.49. 553,515 shares were traded during trading, an increase of 12% from the average session volume of 494,323 shares. The stock had previously closed at $11.83.
A number of research analysts recently weighed in on the company. ValuEngine raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. BidaskClub lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. SunTrust Banks decreased their price objective on Dicerna Pharmaceuticals to $20.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. Finally, Citigroup started coverage on Dicerna Pharmaceuticals in a report on Friday. They issued a “buy” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. Dicerna Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $21.38.
The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. The firm has a market cap of $812.37 million, a P/E ratio of -10.41 and a beta of 2.30.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.16). Dicerna Pharmaceuticals had a negative net margin of 1,284.93% and a negative return on equity of 52.17%. The firm had revenue of $3.11 million during the quarter, compared to analyst estimates of $10.59 million. As a group, equities research analysts predict that Dicerna Pharmaceuticals Inc will post -1.35 EPS for the current year.
In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 15,000 shares of the company’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.00, for a total value of $225,000.00. Following the transaction, the insider now directly owns 39,480 shares of the company’s stock, valued at approximately $592,200. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 19.85% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. grew its holdings in shares of Dicerna Pharmaceuticals by 53.5% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 447,500 shares of the biopharmaceutical company’s stock worth $4,784,000 after purchasing an additional 156,000 shares in the last quarter. Federated Investors Inc. PA grew its holdings in shares of Dicerna Pharmaceuticals by 61,484.1% during the 3rd quarter. Federated Investors Inc. PA now owns 252,495 shares of the biopharmaceutical company’s stock worth $3,853,000 after purchasing an additional 252,085 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Dicerna Pharmaceuticals by 46.0% during the 4th quarter. BlackRock Inc. now owns 4,331,228 shares of the biopharmaceutical company’s stock worth $46,300,000 after purchasing an additional 1,364,155 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Dicerna Pharmaceuticals by 15.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 185,441 shares of the biopharmaceutical company’s stock worth $2,830,000 after purchasing an additional 24,543 shares in the last quarter. Finally, Emory University acquired a new stake in shares of Dicerna Pharmaceuticals during the 4th quarter worth $1,844,000. 89.65% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals (DRNA) Trading 5.6% Higher” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2019/05/24/dicerna-pharmaceuticals-drna-trading-5-6-higher.html.
Dicerna Pharmaceuticals Company Profile (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
Further Reading: How does the Beige Book influence monetary policy?
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.